ADAXION provides a platform that de‑immunizes biologic drugs, preventing the formation of anti‑drug antibodies that can diminish efficacy and cause adverse immune reactions. Its proprietary ADA x technology attaches CD22 ligands to the therapeutic molecule, selectively deleting drug‑specific B cells while preserving the drug’s activity, enabling development of biologics that would otherwise be blocked by immunogenicity concerns.
Funding
Funding not disclosed
Founders
Product
Problem
Biologic therapeutics often trigger anti‑drug antibody (ADA) responses, which can lower drug exposure, diminish efficacy, and cause adverse immune reactions. High immunogenicity limits the development and clinical use of many promising biologic candidates.
Solution
Adaxion’s ADA x platform reduces immunogenicity by covalently attaching proprietary CD22 ligands to the therapeutic molecule. The CD22 ligands selectively target and eliminate B cells that recognize the drug, preventing ADA formation while preserving the biologic’s pharmacological activity. This approach enables developers to advance high‑immunogenicity candidates that would otherwise be excluded due to immune‑related risks. The platform can be applied to a range of protein‑based therapeutics, extending their therapeutic window and improving safety profiles.
Target Audience
Primary customers are pharmaceutical and biotech companies developing protein‑based therapeutics that face immunogenicity challenges, particularly those seeking to advance high‑risk or novel biologic candidates.
Features
- Proprietary CD22 ligand conjugation that directs drug‑specific B‑cell depletion
- Maintains full functional activity of the parent biologic after modification
- Compatible with diverse biologic formats, including antibodies, fusion proteins, and cytokines
- Scalable conjugation process suitable for preclinical and clinical manufacturing
- Integrated preclinical screening to assess deimmunization efficacy and safety